伊立替康腹腔灌注治疗癌性腹腔积液的疗效观察  

Clinical Observation of Abdominal Perfusion with Irinotecan for Malignant Ascites

作　　者：李经忠[1] 丁西平[1] 马林辉 吴学辉 

机构地区：[1]胜利油田中心医院,257000 [2]胜利油田肛肠病防治院,257000

出　　处：《实用癌症杂志》2012年第6期649-650,共2页The Practical Journal of Cancer

摘　　要：目的观察伊立替康40 mg腹腔灌注治疗癌性腹腔积液的效果以及患者的耐受性。方法对50例癌性腹腔积液的患者,随机分为2组,试验组30例腹腔注入伊立替康40 mg,对照组20例腹腔注入顺铂40 mg+5-氟尿嘧啶1.0 g。结果伊立替康组完全缓解12例(40%),部分缓解15例(50%),无效3例(10%),总有效率90%;对照组完全缓解5例(25%),部分缓解7例(35%),无效8例(40%),总有效率60%。2组有效率相比有统计学差异(P<0.05)。毒副作用伊利替康组主要表现为第3天短暂轻度腹泻(30%),短暂轻度白细胞下降(20%);对照组副作用主要表现为第2天轻度腹部不适(20%),轻度腹泻(10%)。结论伊立替康40 mg腹腔灌注治疗恶性腹腔积液,疗效显著,毒副作用患者可耐受。Objective To evaluate the clinic effects and adverse reactions of malignant ascites treated by abdominal perfusion with irinotecan.Methods 50 patients were assigned into two groups randomly,the trial group and the control group.In the trial group,30 cases were treated with irinotecan 40 mg by abdominal perfusion.20 cases in the control group were treated with cisplatin 40 mg and 5-Fluorouracil 1.0 g.Results There were 12 cases（40%） of complete-reactive,15 cases（50%）of partial-reactive,and 3 cases（10%） of non-reactive in the irinotecan group.The overall response rate was 90 % in the irinotecan group.There were 5 cases（25%） of complete-reactive,7 cases（25%） of partial-reactive,8 cases（40%） of non-reactive,overall recactive rate was 60% in the control group.There was remarkable difference between the two groups（χ2 test,P0.025）.The main adverse effect of irinotecan group was minor diarrhea in the third day which was tolerable.Conclusion To use abdominal perfusion of 40mg irinotecan for malignant ascites is effective and preferable to the traditional perfusion chemotherapy.

关 键 词：癌性腹腔积液 伊立替康 顺铂 5-氟尿嘧啶 

分 类 号：R730.6[医药卫生—肿瘤]